AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34018672
Drug: 1-day continuing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day continuing professional development (CPD) education programme on the International Caries Classification and Management System (ICCMS™) and monthly performance feedback
Trial: 32126317
Drug: Supervised group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised group exercise program (twice weekly for 12 weeks)
Trial: 36322381
Drug: Viscosity (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscosity (gel and liquid)
Trial: 32706660
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3D virtual reality and hands-on aromatherapy
Trial: 35633354
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g intravenously) given 12 hr. before skin incision (Group 2)
Trial: 35633354
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g intravenously) given 12 hr. after operation (Group 3)
Trial: 34228855
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) monotherapy for 96 weeks
Trial: 32275363
Drug: Medicinal penetration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicinal penetration on acupoint combined with medication (oral prednisone tablets for 40 days, starting with 10 mg three times a day, reducing by 5 mg every 7 days)
Trial: 34369837
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 300 mg/day for 8 weeks
Trial: 32922107
Drug: Guided imagery-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery-based smoking cessation intervention (details on dosage and duration not available)
Trial: 34333826
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (6-fold of MED as initial dose)
Trial: 34333826
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose (4-fold of MED as initial dose)
Trial: 34333826
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (2-fold of MED as initial dose)
Trial: 33333771
Drug: Oral Rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Rehydration Solution (DD) - carbohydrates: 33 g·L‐1, sodium: 60 ± 3 mmol·L‐1
Trial: 33333771
Drug: Sports Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sports Drink (SD) - carbohydrates: 62 g·L‐1, sodium: 31 ± 3 mmol·L‐1
Trial: 36175936
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate Ringer’s solution (BRS)
Trial: 36175936
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate Ringer’s solution
Trial: 38183121
Drug: Treatment satisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment satisfaction
Trial: 35297463
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continued daily activities
Trial: 34101713
Drug: Hyperbaric prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric prilocaine 50 mg
Trial: 34101713
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 10 mg
Trial: 33113277
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg, daily)
Trial: 33113277
Drug: Sertraline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100 mg, OD)
Trial: 33113277
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg, OD)
Trial: 33113277
Drug: Dapoxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine (30 mg, OD)
Trial: 32316009
Drug: Neural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural therapy (n = 52)
Trial: 32316009
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no neural therapy, n = 61)
Trial: 35263859
Drug: Intravenous selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous selenium selenite for 5 days
Trial: 37943491
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤2 years
Trial: 32524500
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg subcutaneously
Trial: 34076068
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.5 mg/kg IV) in addition to propofol anesthesia for ECT
Trial: 33788463
Drug: Thunder-fire moxibustion
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thunder-fire moxibustion combined with mifepristone (10 mg once a day) for 3 months
Trial: 33788463
Drug: Mifepristone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (10 mg once a day) for 3 months
Trial: 36219978
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (early‐PN)
Trial: 36219978
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (late‐PN)
Trial: 36219978
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition intake
Trial: 33606931
Drug: Tapentadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol (50 mg bid)
Trial: 33606931
Drug: Oxycodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10 mg bid)
Trial: 35872874
Drug: Dexmedetomidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4 μg/(kg·h)
Trial: 35872874
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 μg/(kg·h)
Trial: 35872874
Drug: Dexmedetomidine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.8 μg/(kg·h)
Trial: 35872874
Drug: Dexmedetomidine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.8 μg/(kg·h) in group A3
Trial: 33676882
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (7-day course) + nasal steroids and douching (12-week course)
Trial: 33676882
Drug: Nasal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroids and douching (12-week course)
Trial: 33573598
Drug: Oxycodone for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone for PCIA + transmuscular quadratus lumborum block
Trial: 33573598
Drug: Oxycodone for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone for PCIA
Trial: 32979512
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg on day 1) and nab-paclitaxel (125 mg/m2 on day 1 and day 8, every 3 weeks)
Trial: 35525251
Drug: tenecteplase (0·25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tenecteplase (0·25 mg/kg, maximum 25 mg, intravenous bolus over 10 s)
Trial: 35525251
Drug: alteplase (0·9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alteplase (0·9 mg/kg, maximum 90 mg, 10% as bolus over 1 min and 90% as infusion over 1 h)
Trial: 35231024
Drug: Monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly follow-up (n=1,976)
Trial: 35231024
Drug: Weekly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly follow-up (n=1,802)
Trial: 35231024
Drug: Monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly follow-up (n=976)
Trial: 35231024
Drug: Weekly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly follow-up (n=1,005)
Trial: 35231024
Drug: Monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly follow-up (n=1,873)
Trial: 35231024
Drug: Weekly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly follow-up (n=1,721)
Trial: 32472590
Drug: TACE alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE alone (monotherapy group)
Trial: 34560112
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg each, 2 tablets, total 6 mg)
Trial: 33661539
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics
Trial: 35723939
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (24-unit dose individualized according to crow's feet line distribution)
Trial: 34412104
Drug: Esketamine 84
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine 84 mg nasal spray plus standard of care
Trial: 34412104
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray plus standard of care
Trial: 34861154
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg per day
Trial: 32072695
Drug: Nutrilite™ Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrilite™ Multi Carotene supplement
Trial: 36441522
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral doses of vitamin D3, 14,000 IU for 3 years
Trial: 33998163
Drug: Candesartan 4
RxNorm normalized name: candesartan 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 4 mg q.d.
Trial: 33998163
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients unwilling to take medication)
Trial: 38559896
Drug: Family-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Based Treatment (FBT)
Trial: 35325055
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of antibiotics
Trial: 35325055
Drug: 24-h course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h course of antibiotics
Trial: 36183567
Drug: Parent-administered intervention
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered intervention in NICU
Trial: 33036254
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with poziotinib and manidipine
Trial: 35259151
Drug: Baseline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline treatment levels for those living with HIV
Trial: 34339623
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus trastuzumab (840 mg loading dose, then 420 mg every 3 weeks for pertuzumab; 8 mg/kg loading dose, then 6 mg/kg every 3 weeks for trastuzumab)
Trial: 32162420
Drug: Buprenorphine and
RxNorm normalized name: Buprenorphine and Naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine and naloxone co‐formulation (4:1 ratio: buprenorphine 2 mg + naloxone 0.5 mg)
Trial: 32162420
Drug: Buprenorphine and
RxNorm normalized name: Buprenorphine and Naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine and naloxone co‐formulation (2:1 ratio: buprenorphine 2 mg + naloxone 1 mg)
Trial: 32162420
Drug: Buprenorphine and
RxNorm normalized name: Buprenorphine and Naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine and naloxone co‐formulation (1:1 ratio: buprenorphine 2 mg + naloxone 2 mg)
Trial: 32162420
Drug: Pheniramine maleate
RxNorm normalized name: Pheniramine Maleate
DrugBank: Pheniramine (DB01620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pheniramine maleate (45.5 mg)
Trial: 35839637
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (n = 29)
Trial: 35839637
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n = 27)
Trial: 32924312
Drug: Dentin surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentin surface roughening/cervical groove preparation with round bur
Trial: 32924312
Drug: Dentin surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentin surface roughening/cervical groove preparation with round bur plus flowable composite
Trial: 32924312
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation (cavity cleaning only)
Trial: 32142970
Drug: Watermelon puree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon puree (100% daily for 6 weeks)
Trial: 36657324
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (G)
Trial: 36267853
Drug: Jiuwei Zhenxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiuwei Zhenxin granules (single drug group)
Trial: 36267853
Drug: Jiuwei Zhenxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiuwei Zhenxin granules and alprazolam (combination group)
Trial: 36267853
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly mentioned, but implied as the combination treatment)
Trial: 34553670
Drug: Intra-operative mapping
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative mapping of lymphatic leakage with peri-incisional methylene blue injection and clipping of lymphatics
Trial: 33016169
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment and Hall Technique (ART‐HT)
Trial: 33089408
Drug: 20-mg temozolomide
RxNorm normalized name: temozolomide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg temozolomide capsules (TOZ309)
Trial: 33089408
Drug: 100-mg temozolomide
RxNorm normalized name: temozolomide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg temozolomide capsules (TOZ309)
Trial: 33089408
Drug: Temodal® capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temodal® capsules
Trial: 36415779
Drug: Concurrent application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent application of multiple techniques
Trial: 33058277
Drug: Minimally enhanced
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally enhanced treatment as usual (Control)
Trial: 32781263
Drug: Sintilimab 200
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200 mg plus pemetrexed and platinum
Trial: 35543938
Drug: Panlong needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panlong needling at Jiaji (EX‐B 2) combined with western medication
Trial: 35543938
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication alone (levodopa and benserazide hydrochloride tablets)
Trial: 32975296
Drug: Standard dressing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dressing, elastic compression, and REAC TO-RPR treatment
Trial: 32975296
Drug: Standard dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dressing and REAC TO-RPR treatment
Trial: 35749710
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) at doses of 75-300 mg
Trial: 33691576
Drug: CRMR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRMR treatment (n = 19)
Trial: 36347049
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 2 years
Trial: 33127585
Drug: Possession of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possession of an analgesic cream
Trial: 33127585
Drug: Possession of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possession of an anti-itch cream (pain-irrelevant control object)
Trial: 34479631
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment
Trial: 32510984
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing group
Trial: 32510984
Drug: Warfarin normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin normal sensitivity group (subgroup of genotype-guided dosing)
Trial: 32510984
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard dosing)
Trial: 36053658
Drug: Prescriptions
RxNorm normalized name: BODY PRESCRIPTIONS ANTIBACTERIAL HAND SANITIZER KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions
Trial: 33095999
Drug: Control (AE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (AE or tDCS administered alone)
Trial: 35831626
Drug: PHS (spray)
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHS (spray) + tooth brushing
Trial: 35831626
Drug: PHS (spray)
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHS (spray)
Trial: 35194646
Drug: Manual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual physical therapy including desensitization maneuvers of the central nervous system
Trial: 35403841
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus platinum-based chemotherapy
Trial: 35403841
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy alone
Trial: 34857494
Drug: IV antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV antimicrobial treatment at home only
Trial: 34857494
Drug: IV antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV antimicrobial treatment both at home and in hospital
Trial: 34857494
Drug: IV antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV antimicrobial treatment in hospital only
Trial: 32561663
Drug: Apalutamide (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide (240 mg once daily)
Trial: 32561663
Drug: Apalutamide (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide (average daily dose reduced to 209 mg)
Trial: 33059293
Drug: AMZ001 once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMZ001 once daily (QD)
Trial: 33059293
Drug: AMZ001 twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMZ001 twice daily (BID)
Trial: 32124144
Drug: Integrated oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated oral language and listening comprehension intervention, delivered in small groups of 3 or 4, 4 days per week for 20 weeks
Trial: 32620543
Drug: 20 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg up to 1000 mL of normal saline (fluid bolus group)
Trial: 32620543
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of normal saline (control group)
Trial: 33993331
Drug: Conventional-dose CT
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CT (CDCT, n = 1539)
Trial: 33993331
Drug: Conventional-dose CT
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CT (CDCT)
Trial: 37074807
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g mannitol
Trial: 37074807
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g mannitol